Trial reportBritish journal of cancer2004
Role of natriuretic peptides in the diagnosis and treatment of patients with carcinoid heart disease.
Trial report in British journal of cancer, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.
- A systematic review and meta-analysis of the diagnosis and surgical management of carcinoid heart disease.Frontiers in cardiovascular medicine · 2024Pooled it
- Association Between Plasma Brain Natriuretic Peptide and Overall Survival in Patients With Advanced Cancer: Preliminary Findings.Journal of pain and symptom management · 2019Trial
- NT-proBNP as a neuroendocrine tumor biomarker: beyond heart failure.Endocrine connections · 2023Article
- Carcinoid Heart Disease Management: A Multi-Disciplinary Collaboration.The oncologist · 2023Article
- Role of Cardiac Biomarkers in Cancer Patients.Cancers · 2021Review
- Biomarkers in Small Intestine NETs and Carcinoid Heart Disease: A Comprehensive Review.Biology · 2021Review
- Update in carcinoid heart disease - the heart of the matter.Reviews in endocrine & metabolic disorders · 2021Review
- Surgery and Perioperative Management in Small Intestinal Neuroendocrine Tumors.Journal of clinical medicine · 2020Review
- Carcinoid Heart Disease: a Comprehensive Review.Current cardiology reports · 2019Review
- Carcinoid Heart Disease: Review of Current Knowledge.Texas Heart Institute journal · 2019Review
- Complications from carcinoid syndrome: review of the current evidence.Ecancermedicalscience · 2016Review
- The association of a panel of biomarkers with the presence and severity of carcinoid heart disease: a cross-sectional study.PloS one · 2013Article
- Metastatic carcinoid tumor presenting as right sided heart failure.International journal of endocrinology and metabolism · 2013Article
- Cardiac surgery for carcinoid heart disease in 12 cases.General thoracic and cardiovascular surgery · 2011Article
- Plasma CCN2/connective tissue growth factor is associated with right ventricular dysfunction in patients with neuroendocrine tumors.BMC cancer · 2010Article
- Guidelines for the diagnosis and management of carcinoid tumours. Part 1: the gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group.Current oncology (Toronto, Ont.) · 2006Article
- Diagnosis and treatment in intestinal carcinoid tumors.Current gastroenterology reports · 2005Review
- Valvular Disorders in Carcinoid Heart Disease.Brazilian journal of cardiovascular surgeryReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carcinoid heart disease (CHD) occurs in 20-70% of the patients with metastatic well-differentiated neuroendocrine tumours (NET). We evaluated whether natriuretic peptides (ANP or NT-proBNP) are useful in early detection of CHD. Blood samples from 32 patients with NET were compared with cardiac ultrasound follow-up. CHD was defined as thickening of the tricuspid valve in the presence of grade III-IV/IV tricuspid valve regurgitation. CHD was found in nine out of 32 patients (28%), all with symptoms of the carcinoid syndrome compared to 65% in the 23 patients without CHD (P=0.04). Median levels of NT-proBNP and 5-HIAA were significantly higher in patients with CHD (894 ng l(-1) and 815 micromol 24 h(-1)) compared to those without (89 and 206 ng l(-1), P<0.001 and P=0.007). No significant differences were detected in ANP levels (P=0.11). Dilatation of the right atrium and ventricle as well as thickening of the tricuspid valve and degree of regurgitation were statistically significant correlated with NT-proBNP levels. The accuracy of NT-proBNP in the diagnosis of CHD was higher than that of ANP. A significantly better survival was observed in case of normal NT-proBNP values. In conclusion, NT-proBNP is helpful as a simple marker in the diagnosis of CHD. Survival is better in patients with normal levels of NT-proBNP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.